Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

Michael R Savona, Kathryn Kolibaba, Paul Conkling, Edwin C Kingsley, Carlos Becerra, John C Morris, Robert M Rifkin, Eric Laille, Amy Kellerman, Stacey M Ukrainskyj, Qian Dong, Barry S Skikne, Michael R Savona, Kathryn Kolibaba, Paul Conkling, Edwin C Kingsley, Carlos Becerra, John C Morris, Robert M Rifkin, Eric Laille, Amy Kellerman, Stacey M Ukrainskyj, Qian Dong, Barry S Skikne

Abstract

CC-486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC-486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacokinetic assessment period, 31 patients (MDS n = 18, CMML n = 4, and AML n = 9) entered a clinical phase in which they received CC-486 300 mg once-daily for 21 days of repeated 28-day cycles. Median age was 71 years (range: 53-93); 42% of patients were aged ≥75 years. A total of 5 patients with AML (63%) had prior MDS. Median number of CC-486 treatment cycles was 4 (range: 1-32). The most common treatment-emergent adverse events (TEAEs) were gastrointestinal (84% of patients) and hematologic (81%). Most common grade 3-4 TEAEs were neutropenia (n = 13, 42%) and anemia (n = 9, 29%). Ten patients experienced grade 4 neutropenia. Infrequently, CC-486 dose was interrupted or reduced due to gastrointestinal (n = 5, 16%) or hematologic (n = 6, 19%) TEAEs. Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%. Red blood cell transfusion independence rates in the MDS/CMML and AML subgroups were 33% and 25%, respectively, and 2 MDS/CMML patients attained hematologic improvement as a best response on-study. No baseline gene mutation was predictive of response/nonresponse. CC-486 allows flexible dosing and schedules to improve tolerability or response. Neutropenia in early treatment cycles deserves scrutiny and may warrant initiation of prophylactic antibiotics. KEY POINTS: The safety profile of oral CC-486 was comparable to that of injectable azacitidine; most adverse events were hematological and gastrointestinal. Extended (21-day/cycle) CC-486 dosing induced responses in patients with hematological malignancies, many of whom had prior DNMTi failure.

© 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
A patient who received injectable hypomethylating agents before study entry and attained complete remission during CC‐486 treatment

References

    1. Jones PA. Altering gene expression with 5‐azacytidine. Cell. 1985;40:485‐486.
    1. Jones PA. Effects of 5‐azacytidine and its 2′‐deoxyderivative on cell differentiation and DNA methylation. Pharmacology and Therapeutics. 1985;28:17‐27.
    1. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5‐azacytidine. Recent Results Cancer Res. 1983;84:202‐211.
    1. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27:1803‐1812.
    1. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncol. 2009;10:223‐232.
    1. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27:1850‐1856.
    1. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291‐299.
    1. Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO‐defined acute myeloid leukemia: results from the Austrian Azacitidine registry of the AGMT‐study group. Ann Hematol. 2014;93:1825‐1838.
    1. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher‐risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403‐411.
    1. Ramos F, Thepot S, Pleyer L, et al. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res. 2015;39:296‐306.
    1. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program. Cancer. 2012;118:1014‐1022.
    1. Itzykson R, Thepot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015;39:124‐130.
    1. Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015;56:887‐895.
    1. Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006;107:1839‐1843.
    1. Sadashiv SK, Hilton C, Khan C, et al. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Med. 2014;3:1570‐1578.
    1. Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA‐739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome‐positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c‐ABL therapy. Haematologica. 2015;100:898‐904.
    1. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pre‐transplant therapy with Azacitidine versus induction chemotherapy and post‐transplant outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211‐1218.
    1. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010;150:293‐302.
    1. Griffin PT, Komrokji RS, De Castro CM, et al. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. Am J Hematol. 2015;90:796‐799.
    1. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420‐5431.
    1. Ivanoff S, Gruson B, Chantepie SP, et al. 5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol. 2013;88:601‐605.
    1. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher‐risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA‐001 trial. Haematologica. 2013;98:1067‐1072.
    1. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (>/=75 years) patients with higher‐risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76:218‐227.
    1. Garcia‐Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521‐2527.
    1. Laille E, Shi T, Garcia‐Manero G, et al. Pharmacokinetics and pharmacodynamics with extended dosing of CC‐486 in patients with hematologic malignancies. PLoS One. 2015;10:e0135520.
    1. Garcia‐Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC‐486 (oral azacitidine) in patients with lower‐risk myelodysplastic syndromes. Leukemia. 2016;30:889‐896.
    1. Laille E, Savona MR, Scott BL, Boyd TE, Dong Q, Skikne B. Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. J Clin Pharmacol. 2014;54:630‐639.
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937‐951.
    1. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419‐425.
    1. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642‐4649.
    1. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5‐azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10:176‐182.
    1. Powers HR, Bachar M, Savage N, et al. Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. Hematol Rep. 2014;6:5516.
    1. Gerds AT, Gooley TA, Estey EH, et al. Pre‐transplant therapy with Azacitidine versus induction chemotherapy and post‐transplant outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;8:1211–1218.
    1. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem‐cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie‐Cellulaire and the Groupe‐francophone des Myelodysplasies. J Clin Oncol. 2012;30:4533‐4540.
    1. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85:130‐138.
    1. Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis ‐ current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40:409‐421.
    1. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562‐569.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel